The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis

Most clinical trials of drug-coated balloon (DCB) for the treatment of femoropopliteal artery stenosis chose 12-month primary patency rate (PPR) or 6-month late lumen loss (LLL) as the primary endpoint. It is still debatable whether 6-month LLL can be served as an appropriate surrogate endpoint for...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endovascular therapy 2024-12, p.15266028241300861
Main Authors: Hao, Jun, Wang, Duoer, Zhao, Yanyan, Zhu, Yingxuan, Tinley, Tenzin, Liu, Weida, Li, Wei, Wang, Chuangshi, Wang, Yang
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c183t-2b48c63f7dc0bc26f39291d36187a2ccc797340b031c01399311bfc584992bb93
container_end_page
container_issue
container_start_page 15266028241300861
container_title Journal of endovascular therapy
container_volume
creator Hao, Jun
Wang, Duoer
Zhao, Yanyan
Zhu, Yingxuan
Tinley, Tenzin
Liu, Weida
Li, Wei
Wang, Chuangshi
Wang, Yang
description Most clinical trials of drug-coated balloon (DCB) for the treatment of femoropopliteal artery stenosis chose 12-month primary patency rate (PPR) or 6-month late lumen loss (LLL) as the primary endpoint. It is still debatable whether 6-month LLL can be served as an appropriate surrogate endpoint for 12-month PPR. This study aimed to identify whether LLL can serve as an appropriate surrogate endpoint in peripheral DCB clinical trials, and shed light on the selection of primary outcome for subsequent confirmatory clinical trials of DCB in the treatment of femoropopliteal artery stenosis. The linear regression model was used to evaluate the correlation between 12-month PPR and 6-month LLL. Pooled standardized mean differences (SMDs) and relative gain between the DCB and plain old balloon angioplasty (POBA) group were computed to assess the consistency and surrogacy, using fixed or random effect model as appropriate. The coefficient of variation (CV) was calculated for both endpoints to compare their degree of variation overall and at study level. A total of 34 studies are eligible for this study. A significant negative linear correlation was found between 12-month PPR and 6-month LLL (R =0.67, slope=-0.309, p=0.007). The SMD (DCB-POBA) of LLL and PPR was -0.76 (95% confidence interval [CI]: -0.98, -0.54), and 0.59 (95% CI: 0.46, 0.72) (p=0.18). The pooled relative gain of PPR (43%, 95% CI: 35%, 50%) was significantly lower than that of LLL (72%, 95% CI: 61%, 84%) (p
doi_str_mv 10.1177/15266028241300861
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146569087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146569087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c183t-2b48c63f7dc0bc26f39291d36187a2ccc797340b031c01399311bfc584992bb93</originalsourceid><addsrcrecordid>eNplkc1O3TAQRq2qqFDaB-gGeckmrcd2nHh5SYFWQioSt-vIcSZgSOJgOwseqO-JI342XflbnO-MPEPIN2DfAarqB5RcKcZrLkEwViv4QI6glGUBZck-bpmrYgMOyecY7xnjwAE-kUOhlZSg5BH5t79D2vg5uh6DSc7P1A90tyzBL8GZhPRmDcHfbul87hfv5kTdTK8DTiY8YKLN6GZnzUj3mR_jVv8Z1tui8bnT0zMzjj5bG5PuMGGggw80x4yjSRNmXW5c4OTzRL-MLmF27UJGn-hNwtlHF7-QgyG78evre0z-Xpzvm1_F1Z_L383uqrBQi1TwTtZWiaHqLessV4PQXEMvFNSV4dbaSldCso4JsAyE1gKgG2xZS61512lxTE5fvPn7jyvG1E4uWhxHM6NfYytAqlJpVlcZhRfUBh9jwKHN-8oreWqBtdt12v-ukzsnr_q1m7B_b7ydQzwDwZSMKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146569087</pqid></control><display><type>article</type><title>The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis</title><source>Sage Journals Online</source><creator>Hao, Jun ; Wang, Duoer ; Zhao, Yanyan ; Zhu, Yingxuan ; Tinley, Tenzin ; Liu, Weida ; Li, Wei ; Wang, Chuangshi ; Wang, Yang</creator><creatorcontrib>Hao, Jun ; Wang, Duoer ; Zhao, Yanyan ; Zhu, Yingxuan ; Tinley, Tenzin ; Liu, Weida ; Li, Wei ; Wang, Chuangshi ; Wang, Yang</creatorcontrib><description>Most clinical trials of drug-coated balloon (DCB) for the treatment of femoropopliteal artery stenosis chose 12-month primary patency rate (PPR) or 6-month late lumen loss (LLL) as the primary endpoint. It is still debatable whether 6-month LLL can be served as an appropriate surrogate endpoint for 12-month PPR. This study aimed to identify whether LLL can serve as an appropriate surrogate endpoint in peripheral DCB clinical trials, and shed light on the selection of primary outcome for subsequent confirmatory clinical trials of DCB in the treatment of femoropopliteal artery stenosis. The linear regression model was used to evaluate the correlation between 12-month PPR and 6-month LLL. Pooled standardized mean differences (SMDs) and relative gain between the DCB and plain old balloon angioplasty (POBA) group were computed to assess the consistency and surrogacy, using fixed or random effect model as appropriate. The coefficient of variation (CV) was calculated for both endpoints to compare their degree of variation overall and at study level. A total of 34 studies are eligible for this study. A significant negative linear correlation was found between 12-month PPR and 6-month LLL (R =0.67, slope=-0.309, p=0.007). The SMD (DCB-POBA) of LLL and PPR was -0.76 (95% confidence interval [CI]: -0.98, -0.54), and 0.59 (95% CI: 0.46, 0.72) (p=0.18). The pooled relative gain of PPR (43%, 95% CI: 35%, 50%) was significantly lower than that of LLL (72%, 95% CI: 61%, 84%) (p&lt;0.001). Coefficient of variation of LLL was larger than that of PPR overall in DCB and POBA groups. Although a significant moderate correlation was observed between 12-month PPR and 6-month LLL, PPR shows more conservative and robust than LLL, which may exaggerate clinical benefits. Late lumen loss should be used discreetly depending on different situations and clinical benefits for patients. This study addresses the critical issue of primary endpoint selection in clinical trials of drug-coated balloon for femoropopliteal artery stenosis. By elucidating the moderate correlation between 6-month late lumen loss (LLL) and 12-month primary patency rate (PPR), the findings underscore the limitations of LLL as a surrogate endpoint due to its variability and potential to overstate clinical benefits. The study advocates for the use of 12-month PPR as a more robust and conservative endpoint in pivotal trials, particularly for novel devices. These findings provide clinicians with a nuanced understanding of outcome measures, promoting evidence-based decision-making and regulatory alignment to ensure patient benefits in vascular interventions.</description><identifier>ISSN: 1526-6028</identifier><identifier>ISSN: 1545-1550</identifier><identifier>EISSN: 1545-1550</identifier><identifier>DOI: 10.1177/15266028241300861</identifier><identifier>PMID: 39644164</identifier><language>eng</language><publisher>United States</publisher><ispartof>Journal of endovascular therapy, 2024-12, p.15266028241300861</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c183t-2b48c63f7dc0bc26f39291d36187a2ccc797340b031c01399311bfc584992bb93</cites><orcidid>0000-0002-5642-0800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39644164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hao, Jun</creatorcontrib><creatorcontrib>Wang, Duoer</creatorcontrib><creatorcontrib>Zhao, Yanyan</creatorcontrib><creatorcontrib>Zhu, Yingxuan</creatorcontrib><creatorcontrib>Tinley, Tenzin</creatorcontrib><creatorcontrib>Liu, Weida</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Wang, Chuangshi</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><title>The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis</title><title>Journal of endovascular therapy</title><addtitle>J Endovasc Ther</addtitle><description>Most clinical trials of drug-coated balloon (DCB) for the treatment of femoropopliteal artery stenosis chose 12-month primary patency rate (PPR) or 6-month late lumen loss (LLL) as the primary endpoint. It is still debatable whether 6-month LLL can be served as an appropriate surrogate endpoint for 12-month PPR. This study aimed to identify whether LLL can serve as an appropriate surrogate endpoint in peripheral DCB clinical trials, and shed light on the selection of primary outcome for subsequent confirmatory clinical trials of DCB in the treatment of femoropopliteal artery stenosis. The linear regression model was used to evaluate the correlation between 12-month PPR and 6-month LLL. Pooled standardized mean differences (SMDs) and relative gain between the DCB and plain old balloon angioplasty (POBA) group were computed to assess the consistency and surrogacy, using fixed or random effect model as appropriate. The coefficient of variation (CV) was calculated for both endpoints to compare their degree of variation overall and at study level. A total of 34 studies are eligible for this study. A significant negative linear correlation was found between 12-month PPR and 6-month LLL (R =0.67, slope=-0.309, p=0.007). The SMD (DCB-POBA) of LLL and PPR was -0.76 (95% confidence interval [CI]: -0.98, -0.54), and 0.59 (95% CI: 0.46, 0.72) (p=0.18). The pooled relative gain of PPR (43%, 95% CI: 35%, 50%) was significantly lower than that of LLL (72%, 95% CI: 61%, 84%) (p&lt;0.001). Coefficient of variation of LLL was larger than that of PPR overall in DCB and POBA groups. Although a significant moderate correlation was observed between 12-month PPR and 6-month LLL, PPR shows more conservative and robust than LLL, which may exaggerate clinical benefits. Late lumen loss should be used discreetly depending on different situations and clinical benefits for patients. This study addresses the critical issue of primary endpoint selection in clinical trials of drug-coated balloon for femoropopliteal artery stenosis. By elucidating the moderate correlation between 6-month late lumen loss (LLL) and 12-month primary patency rate (PPR), the findings underscore the limitations of LLL as a surrogate endpoint due to its variability and potential to overstate clinical benefits. The study advocates for the use of 12-month PPR as a more robust and conservative endpoint in pivotal trials, particularly for novel devices. These findings provide clinicians with a nuanced understanding of outcome measures, promoting evidence-based decision-making and regulatory alignment to ensure patient benefits in vascular interventions.</description><issn>1526-6028</issn><issn>1545-1550</issn><issn>1545-1550</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNplkc1O3TAQRq2qqFDaB-gGeckmrcd2nHh5SYFWQioSt-vIcSZgSOJgOwseqO-JI342XflbnO-MPEPIN2DfAarqB5RcKcZrLkEwViv4QI6glGUBZck-bpmrYgMOyecY7xnjwAE-kUOhlZSg5BH5t79D2vg5uh6DSc7P1A90tyzBL8GZhPRmDcHfbul87hfv5kTdTK8DTiY8YKLN6GZnzUj3mR_jVv8Z1tui8bnT0zMzjj5bG5PuMGGggw80x4yjSRNmXW5c4OTzRL-MLmF27UJGn-hNwtlHF7-QgyG78evre0z-Xpzvm1_F1Z_L383uqrBQi1TwTtZWiaHqLessV4PQXEMvFNSV4dbaSldCso4JsAyE1gKgG2xZS61512lxTE5fvPn7jyvG1E4uWhxHM6NfYytAqlJpVlcZhRfUBh9jwKHN-8oreWqBtdt12v-ukzsnr_q1m7B_b7ydQzwDwZSMKg</recordid><startdate>20241207</startdate><enddate>20241207</enddate><creator>Hao, Jun</creator><creator>Wang, Duoer</creator><creator>Zhao, Yanyan</creator><creator>Zhu, Yingxuan</creator><creator>Tinley, Tenzin</creator><creator>Liu, Weida</creator><creator>Li, Wei</creator><creator>Wang, Chuangshi</creator><creator>Wang, Yang</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5642-0800</orcidid></search><sort><creationdate>20241207</creationdate><title>The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis</title><author>Hao, Jun ; Wang, Duoer ; Zhao, Yanyan ; Zhu, Yingxuan ; Tinley, Tenzin ; Liu, Weida ; Li, Wei ; Wang, Chuangshi ; Wang, Yang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c183t-2b48c63f7dc0bc26f39291d36187a2ccc797340b031c01399311bfc584992bb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hao, Jun</creatorcontrib><creatorcontrib>Wang, Duoer</creatorcontrib><creatorcontrib>Zhao, Yanyan</creatorcontrib><creatorcontrib>Zhu, Yingxuan</creatorcontrib><creatorcontrib>Tinley, Tenzin</creatorcontrib><creatorcontrib>Liu, Weida</creatorcontrib><creatorcontrib>Li, Wei</creatorcontrib><creatorcontrib>Wang, Chuangshi</creatorcontrib><creatorcontrib>Wang, Yang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of endovascular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hao, Jun</au><au>Wang, Duoer</au><au>Zhao, Yanyan</au><au>Zhu, Yingxuan</au><au>Tinley, Tenzin</au><au>Liu, Weida</au><au>Li, Wei</au><au>Wang, Chuangshi</au><au>Wang, Yang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis</atitle><jtitle>Journal of endovascular therapy</jtitle><addtitle>J Endovasc Ther</addtitle><date>2024-12-07</date><risdate>2024</risdate><spage>15266028241300861</spage><pages>15266028241300861-</pages><issn>1526-6028</issn><issn>1545-1550</issn><eissn>1545-1550</eissn><abstract>Most clinical trials of drug-coated balloon (DCB) for the treatment of femoropopliteal artery stenosis chose 12-month primary patency rate (PPR) or 6-month late lumen loss (LLL) as the primary endpoint. It is still debatable whether 6-month LLL can be served as an appropriate surrogate endpoint for 12-month PPR. This study aimed to identify whether LLL can serve as an appropriate surrogate endpoint in peripheral DCB clinical trials, and shed light on the selection of primary outcome for subsequent confirmatory clinical trials of DCB in the treatment of femoropopliteal artery stenosis. The linear regression model was used to evaluate the correlation between 12-month PPR and 6-month LLL. Pooled standardized mean differences (SMDs) and relative gain between the DCB and plain old balloon angioplasty (POBA) group were computed to assess the consistency and surrogacy, using fixed or random effect model as appropriate. The coefficient of variation (CV) was calculated for both endpoints to compare their degree of variation overall and at study level. A total of 34 studies are eligible for this study. A significant negative linear correlation was found between 12-month PPR and 6-month LLL (R =0.67, slope=-0.309, p=0.007). The SMD (DCB-POBA) of LLL and PPR was -0.76 (95% confidence interval [CI]: -0.98, -0.54), and 0.59 (95% CI: 0.46, 0.72) (p=0.18). The pooled relative gain of PPR (43%, 95% CI: 35%, 50%) was significantly lower than that of LLL (72%, 95% CI: 61%, 84%) (p&lt;0.001). Coefficient of variation of LLL was larger than that of PPR overall in DCB and POBA groups. Although a significant moderate correlation was observed between 12-month PPR and 6-month LLL, PPR shows more conservative and robust than LLL, which may exaggerate clinical benefits. Late lumen loss should be used discreetly depending on different situations and clinical benefits for patients. This study addresses the critical issue of primary endpoint selection in clinical trials of drug-coated balloon for femoropopliteal artery stenosis. By elucidating the moderate correlation between 6-month late lumen loss (LLL) and 12-month primary patency rate (PPR), the findings underscore the limitations of LLL as a surrogate endpoint due to its variability and potential to overstate clinical benefits. The study advocates for the use of 12-month PPR as a more robust and conservative endpoint in pivotal trials, particularly for novel devices. These findings provide clinicians with a nuanced understanding of outcome measures, promoting evidence-based decision-making and regulatory alignment to ensure patient benefits in vascular interventions.</abstract><cop>United States</cop><pmid>39644164</pmid><doi>10.1177/15266028241300861</doi><orcidid>https://orcid.org/0000-0002-5642-0800</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1526-6028
ispartof Journal of endovascular therapy, 2024-12, p.15266028241300861
issn 1526-6028
1545-1550
1545-1550
language eng
recordid cdi_proquest_miscellaneous_3146569087
source Sage Journals Online
title The Consideration of Appropriate Surrogate Endpoint in Premarket Clinical Trials of Drug-Coated Balloon Catheter for the Treatment of Femoropopliteal Artery Stenosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A37%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Consideration%20of%20Appropriate%20Surrogate%20Endpoint%20in%20Premarket%20Clinical%20Trials%20of%20Drug-Coated%20Balloon%20Catheter%20for%20the%20Treatment%20of%20Femoropopliteal%20Artery%20Stenosis&rft.jtitle=Journal%20of%20endovascular%20therapy&rft.au=Hao,%20Jun&rft.date=2024-12-07&rft.spage=15266028241300861&rft.pages=15266028241300861-&rft.issn=1526-6028&rft.eissn=1545-1550&rft_id=info:doi/10.1177/15266028241300861&rft_dat=%3Cproquest_cross%3E3146569087%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c183t-2b48c63f7dc0bc26f39291d36187a2ccc797340b031c01399311bfc584992bb93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3146569087&rft_id=info:pmid/39644164&rfr_iscdi=true